- $85.82m
- -$65.10m
- 26
- 51
- 45
- 35
Annual income statement for Climb Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 20.9 | 35.7 | 45.1 | 40.3 | 82 |
| Operating Profit | -20.9 | -35.7 | -45.1 | -40.3 | -82 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -20.7 | -47.5 | -45.2 | -35.1 | -73.9 |
| Net Income After Taxes | -20.7 | -47.5 | -45.2 | -35.1 | -73.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -20.7 | -47.5 | -45.2 | -35.1 | -73.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23 | -52 | -45.2 | -35.1 | -73.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.905 | -4.24 | -1.72 | -0.604 | -0.392 |
| Dividends per Share |